RxDoctor Payments Data

Ramon Rivera Schneider, MD

Internal Medicine · Arecibo, PRNPI 1962585521

Payments from drug & device makers

$3,302in general payments, 2019–2025

Across 121 payments — averaging $27.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • E.r. Squibb & Sons, L.L.C.$596
  • Johnson & Johnson$275
  • Eli Lilly Export S.A. Puerto Rico Branch$274
  • Merck$187
  • PBG Puerto Rico LLC$127
  • plus $456 from 7 others

What the payments were for

  • Food & beverage$3,297100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,302 in reported general payments places this provider in the 85th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$7,684
Medicare patients
20
Services billed
124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol97$67,202
TradjentaLinagliptin99$56,292
JanuviaSitagliptin Phosphate88$55,098
SynthroidLevothyroxine Sodium411$21,617
SynjardyEmpagliflozin/Metformin Hcl35$21,589
RytaryCarbidopa/Levodopa18$20,279
EliquisApixaban27$16,200
Trijardy XrEmpaglifloz/Linaglip/Metformin23$13,252
JardianceEmpagliflozin16$11,030
Synjardy XrEmpagliflozin/Metformin Hcl21$9,584
LantusInsulin Glargine,hum.Rec.Anlog116$9,505
Janumet XrSitagliptin Phos/Metformin Hcl14$8,061
Rosuvastatin Calcium423$7,641
Breo ElliptaFluticasone/Vilanterol17$7,044
JanumetSitagliptin Phos/Metformin Hcl17$6,662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta, Synjardy, Trijardy Xr, Jardiance, Synjardy Xr$111$111,747194 claims
MerckJanuvia, Janumet Xr, Janumet$187$69,820119 claims
AstraZenecaFarxiga$1,386$67,20297 claims
AbbVieSynthroid$46$21,617411 claims
Sanofi-aventis U.S. LLCLantus$17$9,505116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Arecibo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →